Finally, we evaluated the in vivo anti-tumor efficacy of two types of anti-PSMA/anti-CD3 (Fab-scFv and scFv-Fab) BsAb-armed T cells, using SCID mice bearing LNCaP tumors (Fig. 7A). Here, FOLH1 is linked to neoplasm.